These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1316071)

  • 41. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.
    Pascual A; García I; Ballesta S; Perea EJ
    Antimicrob Agents Chemother; 1999 Jan; 43(1):12-5. PubMed ID: 9869557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Accumulation of new quinolones in the blood of elderly patients.
    Morita M; Hasuda A; Nakagawa H; Abe Y; Suzuki K
    J Int Med Res; 1993; 21(6):334-41. PubMed ID: 8143888
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Quinolones and phagocytosis].
    Desnottes JF
    Pathol Biol (Paris); 1987 Dec; 35(10 Pt 2):1426-30. PubMed ID: 3325910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of the new quinolone lomefloxacin against Mycobacterium tuberculosis.
    Piersimoni C; Morbiducci V; Bornigia S; De Sio G; Scalise G
    Am Rev Respir Dis; 1992 Dec; 146(6):1445-7. PubMed ID: 1333738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal clearance of lomefloxacin is decreased by furosemide.
    Sudoh T; Fujimura A; Shiga T; Sasaki M; Harada K; Tateishi T; Ohashi K; Ebihara A
    Eur J Clin Pharmacol; 1994; 46(3):267-9. PubMed ID: 8070509
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Penetrability of ofloxacin into cultured epithelial cells and macrophages.
    Une T; Osada Y
    Arzneimittelforschung; 1988 Sep; 38(9):1265-7. PubMed ID: 3066365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
    Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
    Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
    Piddock LJ; Ricci V
    J Antimicrob Chemother; 2001 Dec; 48(6):787-91. PubMed ID: 11733462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics of quinolones in renal insufficiency.
    Fillastre JP; Leroy A; Moulin B; Dhib M; Borsa-Lebas F; Humbert G
    J Antimicrob Chemother; 1990 Oct; 26 Suppl B():51-60. PubMed ID: 2124213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Influence of new quinolones on superoxide anion generation of polymorphonuclear leukocytes].
    Mitani H; Kiyota H
    Kansenshogaku Zasshi; 1992 Jan; 66(1):59-65. PubMed ID: 1328418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects.
    Ferguson J; McEwen J; Al-Ajmi H; Purkins L; Colman PJ; Willavize SA
    J Antimicrob Chemother; 2000 Apr; 45(4):503-9. PubMed ID: 10747828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.
    Kavi J; Stone J; Andrews JM; Ashby JP; Wise R
    Eur J Clin Microbiol Infect Dis; 1989 Feb; 8(2):168-70. PubMed ID: 2498102
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibacterial activity of lomefloxacin.
    Leigh DA; Tait S; Walsh B
    J Antimicrob Chemother; 1991 May; 27(5):589-98. PubMed ID: 1885417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Penetration of pefloxacin and ciprofloxacin into lung tissue.
    Scaglione F; Mezzetti M; Arcidiacono MM; Gattei G; Fraschini F
    J Antimicrob Chemother; 1995 Apr; 35(4):557-9. PubMed ID: 7628993
    [No Abstract]   [Full Text] [Related]  

  • 58. In vitro activity of subinhibitory concentrations of quinolones on urea-splitting bacteria: effect on urease activity and on cell surface hydrophobicity.
    Ramadan MA; Tawfik AF; el-Kersh TA; Shibl AM
    J Infect Dis; 1995 Feb; 171(2):483-6. PubMed ID: 7844396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK; Nisha AK; Bhattacharya SS; Ramamoorthy U; Lal HM
    Indian J Med Res; 1990 May; 91():182-4. PubMed ID: 2397938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.